2% gocce orali

DRUG8 trials

Sponsors

Fondazione European Myeloma Network Italy O.N.L.U.S., Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., European Myeloma Network B.V., Ceska Myelomova Skupina z.s., Emn Trial Office S.r.l. Impresa Sociale, Universita' Degli Studi Di Torino, Emn Trial Office S.r.l. Impresa Sociale

Conditions

Multiple Myeloma relapsed and/or refractoryNewly diagnosed MM patients >= 65 years old or ineligible for autologous stem cell transplantNewly diagnosed multiple myelomaPATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCTRelapsed Multiple MyelomaYOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLSmetastatic castration resistant prostate cancer (mCRPC)symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Phase 2

Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]

Active, not recruitingCTIS2023-506733-30-00

Fondazione European Myeloma Network Italy O.N.L.U.S.Multiple Myeloma relapsed and/or refractory

Start: 2019-05-16Target: 45Updated: 2025-07-15

A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation

Active, not recruitingCTIS2024-511781-37-00

European Myeloma Network B.V., Ceska Myelomova Skupina z.s., Emn Trial Office S.r.l. Impresa SocialeYOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS

Start: 2019-04-16Target: 401Updated: 2025-11-26

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

RecruitingCTIS2024-511660-89-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Start: 2017-06-09Target: 70Updated: 2025-06-06

Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study)

Active, not recruitingCTIS2024-513397-21-00

Emn Trial Office S.r.l. Impresa SocialeRelapsed Multiple Myeloma

Start: 2021-09-16Target: 25Updated: 2025-10-27

MELFLUFEN FOR ELDERLY MYELOMA PATIENTS IN SECOND OR SUBSEQUENT RELAPSE (MELISSA)

WithdrawnCTIS2024-514652-33-00

Fondazione European Myeloma Network Italy O.N.L.U.S.Relapsed Multiple Myeloma

Target: 30Updated: 2025-02-12

Phase 3

CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL (EMN20)

Active, not recruitingCTIS2024-513396-41-00

Fondazione European Myeloma Network Italy O.N.L.U.S.PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

Start: 2019-05-15Target: 340Updated: 2025-12-15

Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)

RecruitingCTIS2024-513422-38-00

European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa SocialeNewly diagnosed multiple myeloma

Start: 2020-09-28Target: 302Updated: 2025-07-23

Phase 4

A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) – Real MM

Active, not recruitingCTIS2024-512049-17-00

Universita' Degli Studi Di TorinoNewly diagnosed MM patients >= 65 years old or ineligible for autologous stem cell transplant

Start: 2018-09-05Target: 450Updated: 2025-12-05